Kornimate/medical-research-clean huggingface dataset:
tooth roots for lateral alveolar ridge augmentation

Conditions: Bone Atrophy, Alveolar

Summary: a deficient alveolar ridge segment in prepara¬tion for implant placement can be regenerated by several techniques. the type of graft material for each patient depends on many factors such as the anatomy, the morphology of the bone defect, type of prosthodontic rehabilitation and patient or clinician preferences. bone graft material should have three properties that made it ideal: a) osteoconduction, it provides scaffolds for bone regeneration; b) osteoinduction, it promotes the recruitment of bone-forming cells and formation of bone and c) osteogenesis, induction of cells in the graft to promote regeneration of the bone. despite of the development of different types of graft material, autogenous bone is still the gold standard for bone augmentation because it exhibits these three mentioned properties. although it has many advantages, autologous bone has some disadvantages such as high resorption rate up to 50 %, limited source and donor site morbidity. allografts, xenografts and alloplastic bone graft are materials that are used in everyday practice and over long period, but their disadvantages are numerous in comparison with autologous bone. allografts can be carrier of some disease and show lack of osteoproliferation, while alloplasts and xenografts show only osteoconduction. according to these facts, it is obvious that there is a need for development an alternative graft material that will surpass these disadvantages.the reconstruction of deficient alveolar ridge defect by the lateral bone augmentation prior to the dental implant placement is predictable and commonly used method. except animal studies, recent clinical studies showed that there is no difference in the osseointegration of titanium implants in deficient alveolar ridges reconstructed with autogenous cortical bone blocks or autogenous teeth.


Eligibility criteria:
inclusion criteria: * age 18 to 60 years * candidate for lateral ridge augmentation * insufficient bone ridge width at the recipient site for implant placement * sufficient bone height at the recipient site for implant placement and (e) * healthy oral mucosa * at least 2 mm keratinized tissue exclusion criteria: * general contraindications for dental and/or surgical treatments * inflammatory and autoimmune disease of the oral cavity, * uncontrolled diabetes (hba1c \> 7%) * history of chemotherapy or radiotherapy within the past five years, * previous immunosuppressant, bisphosphonate or high- dose corticosteroid therapy * smokers * pregnant or lactating women

Keywords: bone augmentation autogenous tooth roots dental implants
investigate effect of secukinumab on the pk of midazolam in patients with mod to sev plaque psoriasis

Conditions: Moderate to Severe Plaque Psoriasis

Summary: to determine whether secukinumab can alter the activity of cytochrome p450 (cyp) 3a4 using midazolam as probe substrate in patients with moderate-to-severe plaque psoriasis.

this will be an open-label, confirmatory study investigating potential disease-drug-drug interaction of secukinumab and midazolam in male and female patients with moderate-to-severe plaque psoriasis. a total of approximately 25 patients are required to obtain at least 20 completers in the study patients who meet the eligibility criteria at screening, will have a baseline assessment day (within 1 week prior to the start of secukinumab) during which a full midazolam pk profile after a single oral dose of 5 mg will be assessed by collecting blood over the 12 hour postdose period. on day 1 (week 0), day 8 (week 1), day 15 (week 2), day 22 (week 3) and day 29 (week 4) patients will receive 300 mg s.c. secukinumab (2 injections of 150 mg s.c.). on day 8 and on day 36 (week 5), patients will receive additional single doses of 5 mg oral midazolam (total of 3 single doses). the midazolam pk profile will be assessed over the 12 hour postdose period. on those days when midazolam pk profiles are assessed, samples will be collected and analyzed for circulating il-6, inflammatory panel (collected at screening, baseline and pre-dose day 1 only), total il-17a (after following initiation of secukinumab treatment), hscrp and for 4-beta-hydroxycholesterol (exploratory endogenous phenotyping marker of cyp3a activity). there will be an extended treatment period during which patients will receive secukinumab 300 mg s.c. at weeks 8, 12, 16, 20 and 24. then there will be a follow-up period of 12 weeks following the last dose administered at week 24. visits will be at weeks 28, 32 and 36.

Eligibility criteria:
inclusion criteria: * moderate to severe plaque psoriasis as defined at baseline by: pasi score of 12 or greater and iga mod 2011 score of 3 or greater (based on a scale of 0 - 4) and body surface area (bsa) affected by plaque-type psoriasis of 10% or greater. * chronic plaque-type psoriasis considered inadequately controlled by: topical treatment and/or; phototherapy and/or previous systemic therapy * men or women at least 18 years of age or older at time of screening. exclusion criteria: * forms of psoriasis other than chronic plaque-type * pregnant or nursing (lactating) women, * history of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection. * subjects with known history of hypersensitivity to midazolam

Keywords: plaque psoriasis disease-drug-drug-interaction midazolam secukinumab
is neutrophil to lymphocyte ratio a prognostic factor of sepsis in newborns with operated neural tube defects?

Conditions: Neural Tube Defects; Newborn Sepsis

Summary: we aimed to investigate whether neutrophil lymphocyte ratio is a prognostic factor of sepsis in newborns with operated neural tube defects?


Eligibility criteria:
inclusion criteria: * \<28 days diagnosed with with neural tüpe defects to be operated exclusion criteria: * \>28 days
myeloma registry platform (myriam)

Conditions: Multiple Myeloma

Summary: the purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with multiple myeloma in germany.

myriam is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of multiple myeloma in germany. the registry will follow patients for up to five years. it will identify common therapeutic sequences and changes in the treatment of the disease. at inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. during the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. health-realted quality of life in patients with multiple myeloma (mylife) will be evaluated for up to five years.

Eligibility criteria:
inclusion criteria: * mm requiring systemic (first-, second- or third-line) treatment (closed for first-line / second-line recruitment) * age ≥ 18 years * written informed consent * patients participating in the pro satellite: signing of informed consent and completion of baseline questionnaire before, but not more than eight weeks before the start of respective systemic treatment * patients not participating in the pro satellite: signing of informed consent not later than four weeks after start of respective treatment, and not more than eight weeks before the start of respective systemic treatment * sufficient german language skills for participation in the pro satellite exclusion criteria: * no systemic therapy for myeloma * patients already enrolled in studies that prohibit any participation in other studies
safety study of of intravenous ccl2-lpm in patients with iga nephropathy

Conditions: IGA Nephropathy; Proteinuria

Summary: the purpose of this study is to evaluate the safety of several dose levels of ccl2-lpm in patients with iga nephropathy who have high levels of protein in the urine.

in spite of adequate blood pressure control and diet, 30 percent of patients with iga nephropathy continue to secrete large amounts of protein in the urine and have a high likelihood of progressing to end-stage renal disease over 5-10 years and eventually requiring dialysis or kidney transplant. in iga nephropathy, the injured kidney tissue secretes a messenger that recruits white blood cells (leukocytes) into the kidney. this messenger is the chemokine, ccl2. as a consequence ccl2 also is excreted into the urine and can be measured as evidence of inflammation in the kidney. this study evaluates the safety of a new potential therapy,ccl2-lpm (leukocyte population modulator), for iga nephropathy. ccl2-lpm is composed of the messenger chemokine, ccl2, fused to an enzyme that inhibits protein production by the leukocytes and prevents the leukocytes from migrating into the kidney. the ccl2 end of the molecule targets only a small subset of leukocytes that have the corresponding receptor for ccl2 on the surface. after ccl2 binds to its receptor it is drawn inside the cell and carries the enzyme into the cell. the targeted cells are prevented from entering the kidney and causing further damage. thus, ccl2-lpm may interrupt the ongoing cycle of inflammation that leads to end-stage renal disease.

Eligibility criteria:
inclusion criteria: * biopsy proven iga nephropathy * gfr \> 30 ml/min * urinary protein \> 700 mg/day * stable serum creatinine * urine ccl2/creatinine \> 250 pg/mg * stable doses of medications * acei and/or arb maximized to control hypertension and proteinuria exclusion criteria: * other causes of nephropathy * pregnant or nursing females * prednisone \> 10 mg/day * other prohibited medications * bp \> 140/90 * bmi \> 35 * concurrent infection requiring treatment * clinical significant concurrent medical conditions * known allergy or sensitivity to formulation ingredients

Keywords: iga nephropathy chemokine fusion protein leukocyte population modulator phase-1
cerebral oxymetry at elective coronary and valve surgery.

Conditions: Coronary Artery Disease.; Aortic Valve Stenosis.; Aortic Valve Regurgitation.

Summary: use of vasopressor to maintain mean arterial pressure on cardio pulmonary bypass can lead to decreased cerebral flow and oxygenation in individual patients and this can be detected by means of cerebral oxymetry.


Eligibility criteria:
inclusion criteria: * patient age under 80. * patients should undergo elective coronary artery bypass grafting surgery (acb) or heart valve surgery (avr or mvr). * the patient must be admitted at least 18 years of years. exclusion criteria: * damage to the frontal lobes corresponding to the area where sco2 monitored. * patients in pharmacological studies. * patients with known intracranial vascular anomalies or cerebral aneurysms. * patients with known neurological disease. * patients with known undergone cerebral insult, tia or carotid stenosis.

Keywords: cerebral oximetry. aortic valve stenosis. aortic valve regurgitation. coronary artery disease.
sequential paclitaxel plus cisplatin chemotherapy and radiotherapy as 1st line treatment for esophageal squamous cell cancer

Conditions: Esophageal Squamous Cell Cancer

Summary: metastatic esophageal squamous cell carcinomas have poor prognosis and majority of patients resistant to chemotherapy in china. in the investigators phase ii clinical trial proceeded before, the combination of paclitaxel with cisplatin showed good tolerance and efficacy to esophageal squamous cell carcinomas. radiotherapy has been indicated as a definitive treatment for unresectable or medically inoperable tumors in escc patients. however, not only the combination with chemotherapy, but also the boundaries of the clinical target volume (ctv) are not internationally defined. the investigators then initiated a prospective phase ii clinical trial with sequential paclitaxel/cisplatin and radiotherapy as the 1st line treatment in metastatic esophageal carcinoma to observe the efficacy and safety of the combination.


Eligibility criteria:
inclusion criteria: * having signed informed consent * age ≥18 years old * histologically confirmed esophageal squamous carcinoma,metastatic disease with primary tumor,no prior palliative chemotherapy; no prior radiotherapy except radiotherapy at non-target lesion of the study more than 3 months * sex is not limited * measurable disease according to the recist criteria(diameter of the lesion should be more than 10mm by spiral ct or mri, more than 20mm by common ct, the date of image should be less than 15 days before enrollment) * karnofsky performance status ≥80 * life expectancy of ≥ 3 month * wbc \> 3,000/mm3, absolute neutrophil count ≥1500/mm3, platelet \> 100,000/mm3, hb \> 9g/dl(within 14 days before enrollment),alt and ast \< 2.5 times uln (≤5 times uln in patients with liver metastases),bilirubin level \< 1.0 times uln,serum akp \< 2.5 times uln,serum creatinine \< 1.5 times uln * no sever complication, such as active gastrointestinal bleeding, perforation, jaundice, obstruction, non-cancerous fever \> 38℃； * normal ecg and heart function * fertile patients must use effective contraception * good compliance exclusion criteria: * previous treatment of palliative chemotherapy * known hypersensitivity to paclitaxel,cisplatin * only with brain or bone metastasis * no measurable lesions, eg. pleural fluid and ascites * suffer from severe heart disease or disease with other important organs * chronic diarrhea or renal dysfunction * pregnancy or lactation period * other previous malignancy within 5 year, except non-melanoma skin cancer chronic diarrhea * mentally abnormal or disable cognition,including cns metastasis
naltrexone for use in conjunction with buprenorphine in adults with opioid use disorder prior to first dose of vivitrol® (naltrexone for extended-release injectable suspension)

Conditions: Opioid Use Disorder

Summary: this study will evaluate the safety, effectiveness and tolerance of low doses of oral naltrexone along with buprenorphine to treat opioid use disorder prior to the first injection of vivitrol.


Eligibility criteria:
inclusion criteria: * willing and able to provide informed consent * willing and able to provide government-issued identification * has a bmi of 18.0-40.0 kg/m\^2 * has a physiologic dependence on opioids * is voluntarily seeking treatment for opioid use disorder and willing to completely withdraw from his/her opioid use throughout the study with desire for or motivation for antagonist therapy * wiling to abide by the contraception requirements for the duration of the study * additional criteria may apply exclusion criteria: * is pregnant, planning to become pregnant or breastfeeding during the study * has used buprenorphine within 7 days prior to randomization * has used methadone within 14 days prior to randomization * has a history of vivitrol use within 90 days prior to screening or has used oral naltrexone within 14 days prior to randomization * has a history of seizures or has received anticonvulsant therapy within the past 5 years * has a condition, disease state, or previous medical history that would preclude safe participation in the study or affect the ability to adhere to the protocol visit schedule, requirements, or assessments * has a current diagnosis of schizoaffective disorder, bipolar disorder, or untreated and unstable major depressive disorder * is currently physiologically dependent on any psychoactive substance (except opioids, caffeine, or nicotine) requiring medical intervention for detoxification * has a history of hypersensitivity or adverse reaction to buprenorphine, naltrexone, or naloxone * has a history of more than 3 unsuccessful inpatient or medically assisted outpatient opioid detoxifications during his/her lifetime * has significant suicidal ideation or behavior within the past year * is currently participating, or has participated, in a clinical trial of an investigational drug, device, or biologics within 3 months prior to screening * has a history of accidental opioid drug overdose in the past 3 years whether or not medical treatment was sought or received * is court mandated to receive treatment for opioid use disorder * additional criteria may apply

Keywords: alkermes buprenorphine naltrexone vivitrol opioid use opiates dependence abuse heroin painkillers substance abuse
art drug dosage adjustment in hiv-infected population

Conditions: HIV Infections

Summary: the purpose of this study is to determine efficacy of the combination of low dose of tenofovir, efavirenz and lamivudine in treating hiv-infection.

the feedback system control (fsc) technique has been developed to rapidly identify optimal combinations for therapeutic purposes. low dose of tdf+3tc+efv combination has been test in vitro study by fsc which showed high efficacy and now the investigators apply it to human to further optimize the art combination.

Eligibility criteria:
inclusion criteria: * hiv antibody positive * hiv rna below 10\*e5 copies/ml * cd4 t cell count above 200 cells/ml * provision of written informed consent exclusion criteria: * hiv genotyping resistant to investigating drug * pregnant, breastfeeding, or lactating * any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with treatment, assessment, compliance with the protocol, or subject safety. this would include any active clinically significant renal, cardiac, pulmonary, vascular, or metabolic (thyroid disorders, adrenal disease) illness, or malignancy * medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol * laboratory blood values: * haemoglobin \<7.0 grams/decilitre (g/dl) * neutrophil count \<500/mm3 * platelet count \<50,000/mm3 * aspartate aminotransferase or alanine transaminase \>5 times upper limit of normal (uln) * subjects with an estimated creatinine clearance of \<50 ml/minute

Keywords: hiv infections tenofovir efavirenz
prevention of pressure ulcers in patients at medium to high risk of developing pressure ulcers and using the domus 4 / auto motorized air mattress

Conditions: Pressure Injury

Summary: the aim of the study is to determine the clinical value of using a powered alternating pressure air mattress (p-apam) in the prevention of pressure injury (pi) in patients at medium to high risk. this study is noncomparative, observational study. patients older than 18 years of age, with a medium to high risk of pi, without pi, up during the day, and lying more than 15 hours a day on a specific p-apam were included. the study was conducted in nursing homes, and in long-stay geriatrics department. patients are followed up for 35 days. the use of the p-apam is associated with the usual pi prevention measures. the primary outcome is the percentage of patients who developed between day 0 and day 35 at least one pi of at least stage 2 on the sacrum, spine, or heel. secondary endpoints are patient assessments of comfort, caregiver satisfaction, mattress noise level, and mattress safety.


Eligibility criteria:
inclusion criteria: patient over 18 years old * patient with a medium to high risk of developing pressure ulcers (clinical judgment and a score of \[10 to 14\] on the braden scale (6 (maximum risk) to 23 (no risk)) * patient without pressure injury on the day of inclusion * patient up during the day, lying between 3 p.m. and 8 p.m. a day on a domus 4 / auto mattress * patient with a weight \< 200 kg * patient (or a trusted third party) having been informed of the study and agreeing to participate exclusion criteria: * patient at end of life (estimated life expectancy less than 6 months) * malnourished patient according to the french health authority (haute autorité de la santé) definition\* \* for adults under 70: * weight loss ≥ 5% in one month or ≥ 10% in six months * or body mass index (bmi) ≤ 18.5 (excluding constitutional thinness) * for adults over 70: * weight loss ≥ 5% in one month or ≥ 10% in six months * or bmi ≤ 21 * or mini nutritional assessment (mna) ≤ 17 (/30) * or albuminemia \< 35 g/l

Keywords: pressure injury life support system beds prevention
clinical application of quantitative ultrasonographic analysis in early kidney injury

Conditions: Patient Admitted to Hospital With Acute Kidney Injury Due to Sepsis

Summary: the purpose of this study was to quantify overall blood flow and renal cortical perfusion in patients with septic acute kidney injury (aki) using ultrasound (us) doppler and contrast-enhanced ultrasound (ceus).

kidney ultrasound is the most widely used imaging modality in initial aki workup as it is widely available and free of complications. it is clinically feasible to use us doppler and contrast-enhanced us (ceus) to detect macroscopic and microscopic changes in renal blood flow, and also cardiac output alterations.the aim was to analyze changes in us doppler and ceus quantitative parameters in patients with septic aki to explore perfusion within the renal parenchyma, and also measure global renal blood flow and cardiac output.

Eligibility criteria:
inclusion criteria: 1. meets the aki diagnostic criteria of the kidney disease: improving global outcomes (kdigo) 2. meets sepsis 3.0 diagnostic criteria for sepsis: infection + sofa ≥ 2 exclusion criteria: 1. urinary tract obstruction, hydronephrosis, etc. 2. left ventricular ejection fraction \ 90 mmhg (measured by transthoracic echocardiography) 3. allergy or adverse reaction to contrast media

Keywords: acute kidney injury contrast-enhanced ultrasound renal perfusion microcirculation
aripiprazole treatment of prodromal patients

Conditions: Schizophrenia; Psychosis

Summary: we hypothesize that symptoms will improve in patients who meet diagnostic criteria for the schizophrenia prodrome when they are prescribed aripiprazole.

this is an 8 week trial with extension for responders out to one year. all patients receive active medication; there is no placebo. patients must meet criteria for the schizophrenia prodrome according to the structured interview for prodromal syndromes. patients receive counseling as well. all counseling and medication are free of charge.

Eligibility criteria:
inclusion criteria: * age 13 to 40 meet criteria for the prodrome for schizophrenia exclusion criteria: * history of psychosis

Keywords: prodrome ultra high risk aripiprazole